EVOLVED BY WOUND CARE EXPERTS — YOU

Four therapies, one V.A.C. ULTA™ 4 Therapy System
V.A.C. ULTA™ 4 THERAPY SYSTEM

The result of our continuing commitment to wound care innovation based on clinician and patient needs. More convenient, easier to use, same outcomes.

ADVANCED TECHNOLOGY MADE SIMPLE — SO YOU CAN MOVE ON TO WHAT'S NEXT

- **Efficient**: One device, four therapies
- **Intuitive**: Simplified navigation means less training time
- **Familiar**: Compatible with most of the existing V.A.C.® Therapy accessories
- **Adaptable**: Choose new Tap and Begin (TAB) quick-start default based on clinical data or choose customized therapy
- **Insightful**: Access to 24 hour and cumulative Therapy Information Monitoring (TIM) data
- **Proactive**: Early Detection System (EDS) notifies if leak is present and an alert will occur soon if not addressed

Start therapy in fewer steps with the V.A.C. ULTA™ 4 Therapy System

Easier initiation of V.A.C.® Therapy and V.A.C. VERAFLÔ Therapy:

- **Up to 43% reduction in number of menus**
- **Up to 40% reduction in number of button pushes**
TIME AFTER TIME, IT’S V.A.C.® THERAPY

The technology you trust to deliver the outcomes you need. That’s the proven Certainty of Acelity™

SENSAT.R.A.C.™ Technology: Proprietary technology that continuously monitors and maintains pressure at the wound site by adjusting pump output and compensating for wound distance, position and exudate characteristics.

EASYCLEAR PURGE™ Technology: Aids in the prevention and clearance of blockages by forcing air periodically through outer lumens.

SEAL CHECK™ Leak Detector: Visual cues offer instant feedback to help identify leaks.

95% of published NPWT clinical evidence is based on V.A.C.® Therapy¹

10M wounds treated worldwide with V.A.C.® Therapy ²

¹Excluding PREVENA™ Therapy

²Excluding PREVENA™ Therapy
V.A.C. VERAFLÒ™ THERAPY

Combines the benefits of V.A.C.® Therapy with automated solution distribution and removal:

- **Volumetric delivery**: Automated pump delivers topical wound solutions
- **Fill assist**: Monitor the correct instill volume and save data for future use
- **Dressing soak**: Instill topical wound solution into the wound for easier dressing removal and increased patient comfort

**New Features in V.A.C. VERAFLÒ™ Therapy**:

- **Instillation Connectors**: Redesigned with wings to make connection and disconnection easier
- **Hanger Arm Extension**: Provides additional clearance to help reduce tubing kinks that can cause Solution Bag/Bottle Empty Alerts
- **Now with the ability to track 24 hour and cumulative instillation volume**

When V.A.C.® Therapy alone is not enough.

In a retrospective historical cohort controlled study of infected wounds requiring operative debridement, V.A.C. VERAFLÒ™ Therapy with Prontosan® Instillation was compared to standard V.A.C.® Therapy and demonstrated:

- **94% REDUCTION IN LENGTH OF STAY**
- **94% WOUNDS CLOSED AT DISCHARGE VS. 62% WITH V.A.C.® THERAPY ALONE**
- **SAVINGS PER PATIENT**
  - **$8,613** IN THE 6 MIN. DWELL TIME GROUP
  - **$9,117** IN THE 20 MIN. DWELL TIME GROUP

---

1. Based on 20 minute dwell time and calculation of % reduction (11.4+/-5.1 vs. 14.92 +/-9.2) (p=0.034).
2. Based on 6 minute dwell time (p=0.0001).
3. Calculation of cost savings based on reduced length of hospital stay. Actual savings will vary based on individual facility costs, protocol and patients.
From trauma wounds to pressure ulcers, it’s the same NPWT you rely on today to provide positive outcomes:

• Promote granulation tissue formation
• Decrease wound margins
• Remove exudate
• Remove infectious material
• Reduce edema

Not all NPWT is V.A.C.® Therapy.
A retrospective observational database analysis conducted on records from 21,638 hospitalized patients by Premier Research Services compared V.A.C.® Therapy vs. other NPWT products and demonstrated:

**10% LOWER LENGTH OF STAY**

**11% LOWER TOTAL HOSPITAL CHARGES**

$14,500 DECREASE IN HOSPITAL CHARGES PER PATIENT

*Calculation of % reduction based on 13.0 days (V.A.C.® Therapy vs. 14.5 days (other NPWT). (p<0.001).
**Calculation of % reduction based on $112,759 (V.A.C.® Therapy vs. $127,272 (other NPWT). (p=0.001).
PREVENA™ THERAPY

Optimal management of linear and non-linear incisions:
• Helps to hold incision edges together
• Removes fluids and infectious materials
• Acts as a barrier to external contamination

Simple application and transfer:
• Unique, integrated PEEL & PLACE™ Dressings

Easy out-patient transfer without removing dressing:
• SEAL CHECK™ Feature: Indicates if the seal is intact for transfer to PREVENA™ 125 or PREVENA PLUS™ Therapy Units

Incisions can be complicated and costly.
A randomized study evaluating negative-pressure therapy to decrease vascular groin wound complications in 140 patients compared PREVENA™ Therapy to standard gauze dressings in high risk patients and demonstrated:

<table>
<thead>
<tr>
<th>Reduction</th>
<th>Percentage</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in major wound complications</td>
<td>61%</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Reduction in readmission rates</td>
<td>59%</td>
<td>&lt;0.04**</td>
</tr>
<tr>
<td>Reduction in mean total cost per patient</td>
<td>$6,045</td>
<td>0.115</td>
</tr>
</tbody>
</table>

*Calculation of % reduction based on complication rate reduction in high risk incision patients - 8.5% PREVENA™ Therapy System vs. 21.7% Standard Gauze Dressing (p<0.001).
**Calculation of % reduction based on readmission rate reduction in high risk incision patients - 6.8% PREVENA™ Therapy System vs. 16.7% Standard Gauze Dressings (p<0.04).
ABTHERA™ THERAPY

Designed for simplicity and rapid application to actively manage the open abdomen:

• Provides medial tension, which helps minimize fascial retraction and loss of domain
• Provides continuous negative pressure to remove high-volume exudate and help reduce edema

Take the guesswork out of managing leaks:

• **Early Detection System (EDS):** Provides visual feedback to help identify leaks before an alert/alarm occurs
• **Leak Alert with Continuous Pump:** In the event of a leak alert, the pump will continue to operate, exactly like the current ABTHERA™ Therapy Unit

Prospective study of ABTHERA™ Therapy showed improved 30-day results compared to Barker’s vacuum-packing technique in trauma and surgical patients:

- **53% Reduction in All-Cause Mortality Rate***
- **35% More Likely to Achieve Primary Fascial Closure**

Study Note: Study 1:168 trauma and surgical patients (n=111 for ABTHERA™ Therapy, n=57 for Barkers Vacuum Packing Technique)

*Calculation of % reduction based on 30 day all-cause mortality rates - 14% ABTHERA™ Therapy System vs. 30% BVPT. (p=0.01).
**Calculation based on PFC closure rates - 69% ABTHERA™ Therapy System vs. 51% rate BVPT. (p=0.03).
For more information about the V.A.C. ULTA™ 4 Therapy System, contact your ACELITY sales representative or visit acelity.com

Reference:
4. A retrospective observational database study was conducted by Premier Research services to evaluate the costs and readmission rates of NPWT patients at facilities using KCI versus competitor therapies. Data analyses from 144 hospitals for KCI and 24 for competitor from 07/2011 to 06/2013; KCI n=18,385, Competitor n=3,253. PRS included only those hospitals using procedural cost accounting. Dual hospitals were excluded. Patient cases were included for all indicated wound types. Data points falling in the lower and upper .05% were considered outliers and removed from summary calculations. Research funded by KCI.

NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.